Beam Therapeutics BEAM Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's accrued expenses and other liabilities?
- Beam Therapeutics (BEAM) reported accrued expenses and other liabilities of -$16.26M in Q1 2026.
- How has Beam Therapeutics's accrued expenses and other liabilities changed year-over-year?
- Beam Therapeutics's accrued expenses and other liabilities increased by 11.9% year-over-year, from -$18.46M to -$16.26M.
- What is the long-term trend for Beam Therapeutics's accrued expenses and other liabilities?
- Over 2 years (2021 to 2024), Beam Therapeutics's accrued expenses and other liabilities has grown at a 14.6% compound annual growth rate (CAGR), from $43.91M to -$57.69M.